Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
holding | CATX | Common Stock | 37.6K | Feb 3, 2023 | Direct | ||||||
holding | CATX | Common Stock | 60K | Feb 3, 2023 | By IRA of Spouse | ||||||
holding | CATX | Common Stock | 10K | Feb 3, 2023 | By Child |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
holding | CATX | Stock Options (right to buy) | Feb 3, 2023 | Common Stock | 8.45M | Direct | F1, F2 |
Id | Content |
---|---|
F1 | Fully vested as of 2/3/2023 due to acceleration as a result of merger of Viewpoint Molecular Targeting, Inc. into wholly owned subsidiary of Isoray, Inc. (the "Merger"). |
F2 | Received in exchange for options to acquire 2,672,000 shares of common stock in Viewpoint Molecular Targeting, Inc. at an adjusted exercise price of $0.13 per share pursuant to the terms of the Merger. |